Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech (NASDAQ: ONCY) held its Annual General Meeting (AGM) on August 8, 2025, with 37.42% of outstanding shares represented. The company successfully elected eight directors to its board, with approval rates ranging from 80.45% to 91.64%. The highest approval was received by Jared Kelly (91.64%), while Jonathan Rigby received the lowest support (80.45%).
Shareholders also approved additional resolutions, including fixing the board size at eight members and appointing auditors. The meeting results demonstrate strong shareholder support for the company's governance structure.
Oncolytics Biotech (NASDAQ: ONCY) ha tenuto la sua assemblea generale annuale (AGM) l'8 agosto 2025, con il 37,42% delle azioni in circolazione rappresentate. Sono stati eletti con successo otto amministratori, con tassi di approvazione compresi tra il 80,45% e il 91,64%. Il massimo sostegno è stato ottenuto da Jared Kelly (91,64%), mentre Jonathan Rigby ha ricevuto il livello di supporto più basso (80,45%).
I soci hanno inoltre approvato ulteriori delibere, tra cui la conferma del consiglio in otto membri e la nomina dei revisori. I risultati evidenziano un solido sostegno degli azionisti alla struttura di governance della società.
Oncolytics Biotech (NASDAQ: ONCY) celebró su junta general anual (AGM) el 8 de agosto de 2025, con el 37,42% de las acciones en circulación representadas. La compañía eligió con éxito a ocho consejeros, con tasas de aprobación que oscilaron entre el 80,45% y el 91,64%. Jared Kelly recibió el mayor respaldo (91,64%), mientras que Jonathan Rigby obtuvo el apoyo más bajo (80,45%).
Los accionistas también aprobaron otras resoluciones, entre ellas fijar el tamaño del consejo en ocho miembros y nombrar a los auditores. Los resultados reflejan un sólido apoyo de los accionistas a la estructura de gobierno de la compañía.
Oncolytics Biotech (NASDAQ: ONCY)는 2025년 8월 8일 연례 주주총회(AGM)를 개최했으며 발행주식의 37.42%가 대표되었습니다. 이사회 구성원 8명이 모두 성공적으로 선임되었고 승인률은 80.45%에서 91.64% 사이였습니다. 가장 높은 지지를 받은 것은 Jared Kelly(91.64%)였고, Jonathan Rigby는 가장 낮은 지지(80.45%)를 받았습니다.
주주들은 이사회 규모를 8명으로 확정하고 감사인을 선임하는 등 추가 안건들도 승인했습니다. 이번 의결 결과는 회사의 거버넌스 구조에 대한 주주들의 강한 지지를 보여줍니다.
Oncolytics Biotech (NASDAQ: ONCY) a tenu son assemblée générale annuelle (AGM) le 8 août 2025, avec 37,42% des actions en circulation représentées. La société a élu avec succès huit administrateurs, les taux d'approbation variant de 80,45% à 91,64%. Jared Kelly a obtenu la plus forte approbation (91,64%), tandis que Jonathan Rigby a reçu le soutien le plus faible (80,45%).
Les actionnaires ont également approuvé d'autres résolutions, notamment le maintien du conseil à huit membres et la nomination des commissaires aux comptes. Ces résultats témoignent d'un solide soutien des actionnaires à la gouvernance de la société.
Oncolytics Biotech (NASDAQ: ONCY) hielt am 8. August 2025 seine jährliche Hauptversammlung (AGM) ab, bei der 37,42% der ausstehenden Aktien vertreten waren. Das Unternehmen wählte erfolgreich acht Direktoren, mit Zustimmungsraten zwischen 80,45% und 91,64%. Die höchste Zustimmung erhielt Jared Kelly (91,64%), die niedrigste Jonathan Rigby (80,45%).
Die Aktionäre stimmten zudem weiteren Beschlüssen zu, darunter die Festlegung der Vorstandsgröße auf acht Mitglieder und die Bestellung der Abschlussprüfer. Die Ergebnisse zeigen eine starke Unterstützung der Aktionäre für die Governance-Struktur des Unternehmens.
- None.
- None.
On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:
Director | For | % | Withheld | % |
Patricia Andrews | 10,498,328 | 88.83 % | 1,320,714 | 11.17 % |
Deborah M. Brown | 10,115,110 | 85.58 % | 1,703,932 | 14.42 % |
Jared Kelly | 10,830,605 | 91.64 % | 988,437 | 8.36 % |
Angela Holtham | 10,175,887 | 86.10 % | 1,643,155 | 13.90 % |
James T. Parsons | 10,172,958 | 86.07 % | 1,646,084 | 13.93 % |
Wayne Pisano | 10,148,894 | 85.87 % | 1,670,148 | 14.13 % |
Jonathan Rigby | 9,508,770 | 80.45 % | 2,310,272 | 19.55 % |
Bernd R. Seizinger | 10,269,441 | 86.89 % | 1,549,601 | 13.11 % |
In addition to the election of all nominees listed as directors in the management information circular, dated June 18, 2025, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year.
For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at https://www.sedarplus.ca/home/. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com
Logo - https://mma.prnewswire.com/media/2408622/5454862/Oncolytics_Biotech_Inc_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-302526856.html
SOURCE Oncolytics Biotech® Inc.
FAQ
What was the shareholder participation rate at Oncolytics Biotech's (ONCY) 2025 AGM?
Who received the highest approval rating among ONCY's director nominees in 2025?
How many directors were elected to Oncolytics Biotech's board in 2025?
What was the lowest approval rating received by an ONCY director nominee in 2025?
